# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT06714617 ‚öîÔ∏è

**Trial Name**: Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advan...  
**Patient**: Ayesha Kiani (ID: ayesha_001)  
**Generated**: 2025-11-15T06:50:17.811922  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: GOOD_TIER  
**Composite Score**: 0.67/1.00  
**Eligibility Probability**: ~50%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT06714617

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: ACTIVE_NOT_RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: ACTIVE_NOT_RECRUITING
‚úÖ Gynecologic cancer trial match
‚úÖ Advanced eligible (patient: IVB)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 1 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~50% (pending biomarkers)

**Semantic Similarity**: 0.819 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~50%  
**Calculation**: P(HER2-) = 0.50 (literature, pending test)

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

### **Clinical Trial Analysis: NCT06714617**

**Note**: This is a structured fallback analysis (LLM unavailable).

#### **1. Drug Mechanism Fit**
The trial "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors" requires detailed mechanism analysis. Review the trial protocol to understand how the investigational drug addresses Ayesha's Stage IVB High-Grade Serous Ovarian Carcinoma with extensive tumor burden and pleural metastases.

#### **2. Location Logistics**
Review trial locations to identify NYC metro sites accessible from ZIP 10029 (East Harlem). Preferred centers: Mount Sinai (local), MSK (2 miles), NYU Langone (3-4 miles).

#### **3. Risk-Benefit for Ayesha**
**Key Considerations**:
- Pulmonary compromise: Large bilateral pleural effusions require careful monitoring
- ECOG 1: Acceptable for most trials, but toxicity profile is critical
- Tumor burden: Extensive disease (CA-125 >2800) may require aggressive initial treatment

#### **4. Comparison to Standard of Care**
Ayesha's planned SOC is Carboplatin + Paclitaxel + Bevacizumab (NCCN-guideline first-line therapy for Stage IVB HGSOC, BRCA wildtype). This trial should be compared to this regimen to assess:
- Is it a replacement for SOC (frontline trial)?
- Is it additional to SOC (maintenance trial)?
- Is it an alternative if SOC fails?

#### **5. Critical Considerations**
1. **Biomarker testing**: HER2 and HRD status are unknown - may be required for enrollment
2. **Timing**: When should Ayesha enroll? Before SOC, during SOC, or after response?
3. **Clinical team review**: Discuss with Ayesha's oncologist before enrollment decisions

**Recommendation**: Full protocol review with clinical team required.


---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~50%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT06714617

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT06714617
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~50%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
Inclusion Criteria:

1. Signed the informed consent form
2. Age ‚â•18 years.
3. Weighs more than 40 kg. For doses \<0.3 mg/kg, subject must weigh ‚â•70 kg.
4. Has a life expectancy of ‚â•3 months.
5. Has documented locally advanced or metastatic HER2-positive solid tumor(s) (IHC 1+ to 3+ or in situ hybridization \[ISH\] positive) or HER2-mutant tumor specimen not amenable to curative surgery or radiation and has received at least 1 line of standard therapy in the advanced/metastatic setting, or for which no standard treatment is available, including:

   1. Cohort 1: HER2-positive breast cancer (BC);
   2. Cohort 2: HER2-positive gastric/gastroesophageal junction cancer (GC/GEJ);
   3. Cohort 3: HER2-positive or HER2-mutant non-small cell lung cancer (NSCLC);
   4. Cohort 4: HER2-positive endometrial cancer (EC);
   5. Cohort 5: HER2-positive ovarian cancer (OC), including fallopian tube cancer and primary peritoneal cancer;
   6. Cohort 6: HER2-positive urothelial cancers (UC);
   7. Cohort 7: Other HER2-positive solid tumors as approved by the medical monitor. Note: For indications in which a HER2-directed therapy is approved, the approved treatment is recommended although not mandated, at the discretion of the investigator.
6. Agree to provide most recent existing tumor samples (FFPE tissue block or slides) from primary or metastatic sites for tissue-based IHC staining to centrally determine HER2 expression:

   1. In dose escalation and dose finding: archival tissue or fresh biopsy. If no archival tissue is available or it is not possible to obtain a fresh tissue biopsy, medical monitor approval is required;
   2. In dose expansion: an FFPE block or slides from fresh biopsy or the most recent archival tissue is required.
7. Has at least one measurable lesion based on RECIST (Response Evaluation Criteria in Solid Tumors) V1.1.
8. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
9. Toxicity of previous antitumor therapy has returned to Grade ‚â§1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ‚â§2.
10. No serious cardiac dysfunction and left ventricular ejection fraction ‚â•50%.
11. Has adequate organ function before enrollment, defined as:

    1. Marrow function: Absolute neutrophil count (ANC) ‚â•1.5√ó109/L, platelet count ‚â•100√ó109/L, hemoglobin (Hb) ‚â•9.0 g/dL (blood transfusion, platelet transfusion, erythropoietin, platelet-stimulating agents, and G-CSF use are not allowed 1 week prior to screening);
    2. Hepatic function: Total bilirubin (TBIL) ‚â§1.5√óULN (‚â§3√óULN for subjects with Gilbert's syndrome or liver metastasis at baseline), AST and ALT without liver metastasis ‚â§3.0√óULN, AST and ALT with liver metastasis ‚â§5.0√óULN;
    3. Renal function: Creatinine (Cr) clearance ‚â•60 mL/minute (Cockcroft-Gault equation).
12. Coagulation parameters: International normalized ratio (INR) ‚â§1.5√óULN, and activated partial thromboplastin time (aPTT) ‚â§1.5√óULN, unless receiving anticoagulation therapy with PT and aPTT levels within the intended therapeutic range.
13. Urine protein ‚â§2+ or ‚â§1000 mg/24 hours.
14. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended.
15. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female subjects are considered WOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \>45 years old in the absence of other biological or physiological causes. In addition, females \<55 years old must have a serum follicle stimulating hormone (FSH) level \>40 mIU/mL to confirm menopause.

Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible for participation in this study:

1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration.
2. Concomitant use of strong inhibitors and inducers of any CYP3A4 enzyme or P-gp transporter system within 2 weeks or 5 half-lives (whichever is longer) prior to the first administration and throughout all parts of the study.
3. History of severe heart disease, such as symptomatic congestive heart failure (CHF) ‚â• Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ‚â• Grade 2 heart failure at any time, or history of myocardial infarction or unstable angina pectoris within 6 months before enrollment.
4. Prolonged QT interval (QTcF \>470 msec), complete left bundle branch block, Grade 3 atrioventricular block, or a history of additional risk factors for torsades de pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP.
5. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for type 1 diabetes, hypothyroidism that can be controlled by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis).
6. Other prior malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years prior to screening.
7. Poorly controlled hypertension by two types of antihypertensive drugs (systolic blood pressure \>150 mmHg or diastolic blood pressure \>100 mmHg).
8. Advanced or clinically significant lung diseases, such as poorly controlled chronic obstructive pulmonary disease and asthma, restrictive lung disease, pulmonary hypertension etc.
9. Have a history of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
10. Stroke or transient ischemic attack (TIA) within 6 months before enrollment.
11. Thromboembolic event (eg, deep vein thrombosis \[DVT\] or pulmonary embolism \[PE\]) within 6 months before enrollment except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before enrollment.
12. Primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded. Patients with previously treated brain metastas...

---

## üìä TRIAL DESCRIPTION

The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Yale Cancer Center** - New Haven, Connecticut

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

### HER2 Testing (Priority: P0 - URGENT)
**Status**: PENDING  
**Test**: HER2 IHC (ASCO-CAP gastric scoring)  
**Turnaround**: 3-5 days  
**Cost**: $200-400  
**Rationale**: HER2 status unknown - testing required. If IHC 1+/2+ (expression, not amplification), Ayesha may be eligible for breakthrough T-DXd trial.


---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: ‚ö†Ô∏è **P1 - HIGH PRIORITY** (Eligibility: ~50%)

**Next Steps**:
1. **Review eligibility carefully** (with oncologist)
2. **Order pending biomarker tests** (if required)
3. **Contact trial site** (within 1 week)
4. **Backup option** (if top-tier trials fail)


---

## üéØ VALUE PROPOSITION

**WIN-WIN SCENARIO**:
- If eligible (50% chance) ‚Üí Access to experimental therapy
- If not eligible ‚Üí Gets proven SOC (PARP or bevacizumab maintenance)
- Either way, Ayesha receives appropriate care

**Risk-Benefit**: Low risk (pre-screening doesn't commit to enrollment), high reward (cutting-edge therapy)

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.819  
**Composite Score**: 0.67 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 0.30, Stage 4: 0.50)  
**LLM Analysis**: Gemini None  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
